araag2/HINT huggingface dataset:
Clinical trial NCT02006472 (phase 2, status: completed)
Conditions: huntington's disease
ICD codes: G10
Drugs: pridopidine
SMILES: CCCN1CCC(CC1)C1=CC=CC(=C1)S(C)(=O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of HD based on the presence of >/= 36 CAG repeats

          -  Male or female age ≥21 years, with an onset of HD after 18 years' old.

          -  Females of child bearing potential have to be compliant in using adequate birth
             control throughout the duration of the study

          -  Body weight ≥50 kg

          -  Sum of >/= 25 points on the UHDRS-TMS and UHDRS Independence Score below 90%

          -  Able and willing to provide written informed consent prior to any study related
             procedure.

          -  Willing to provide a blood sample for genetic analyses

          -  Willing and able to take oral medication and able to comply with the study specific
             procedures.

          -  Ambulatory, being able to travel to the study centre, and judged by the investigator
             as likely to be able to continue to travel for the duration of the study.

          -  Availability and willingness of a caregiver, informant or family member to accompany
             the patient to the clinic at study, and the suitability of the caregiver should be
             judged by the investigator.

               -  Other criteria apply, please contact the investigator for more information.

        Exclusion Criteria:

          -  Patients with clinically significant heart disease at the screening visit

          -  Treatment with tetrabenazine within 6 weeks of study screening

          -  Patients with a history of epilepsy or of seizures within the last 5 years

          -  Have other serious medical illnesses in the opinion of the investigator may put the
             patient at risk when participating in the study or may influence the results of the
             study or affect the patient's ability to take part in the study

          -  Patients receiving medications (within the last 6 weeks prior to screening) that have
             been proven to prolong QT interval or who may require such medications during the
             course of the study such as but not limited to non allowed anti psychotic medications,
             tricyclic antidepressants and/or Class I antiarrhythmics

          -  Patients receiving medications (within the last 6 weeks prior to screening) that are
             metabolized by CYP2D6 and have the potential of reducing seizure threshold

               -  Other criteria apply, please contact the investigator for more information
Clinical trial NCT02008318 (phase 2/phase 3, status: completed)
Conditions: myelodysplastic syndromes
ICD codes: D46.9, D46.C, D46.Z
Drugs: galunisertib, placebo
SMILES: CC1=CC=CC(=N1)C1=NN2CCCC2=C1C1=C2C=C(C=CC2=NC=C1)C(N)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of MDS based on the World Health Organization (WHO) criteria

          -  Participants with 5q deletions are allowed only if they have failed or are intolerant
             of lenalidomide treatment

          -  Participants must have a Revised International Prognostic Scoring System (IPSS-R)
             category of very low-, low-, or intermediate-risk disease

          -  In the 8 weeks prior to registration, participants in phase 2 should have anemia with
             Hb ≤10.0 g/dL (based on the average of 2 baseline measurements and untransfused for at
             least 1 week) with or without red blood cell (RBC) transfusion dependence confirmed
             for a minimum of 8 weeks before enrollment

          -  For phase 3, participants should have anemia with RBC transfusion dependence confirmed
             within 8 weeks before enrollment

          -  Performance status ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale

        Exclusion Criteria:

          -  No history of moderate or severe cardiac disease

          -  No prior history of acute myeloid leukemia (AML)
Clinical trial NCT02011451 (phase 2, status: withdrawn)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: 95% pure ecgc capsules 200mg, placebo comparator:
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    unable to enroll
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of MS by McDonald criteria

          -  Relapsing-remitting MS or secondary progressive MS

          -  Stable therapy with Copaxone, Rebif, Betaseron or Avonex 30 mcg for at least six
             months

          -  EDSS Score less than or equal to 7.0

          -  Ages 18-60.

          -  Participants must have normal organ and marrow function as defined below:

               -  Leukocytes ≥3,000/µL

               -  Absolute neutrophil count ≥1,500/µL

               -  Platelets ≥100,000/µL

               -  Total bilirubin ≤local upper limit of normal

               -  AST (SGOT) ≤local upper limit of normal

               -  ALT (SGPT) ≤local upper limit of normal

               -  Creatinine ≤local upper limit of normal

        Exclusion Criteria:

          -  MS relapse within the 30 days prior to enrollment

          -  A primary progressive form of MS.

          -  Previous treatment prior to study entry as follows: complete radiation ablation of the
             bone marrow or anti-CD4 antibody treatment (Campath) at any time; mitoxantrone,
             cyclophosphamide, Natalizumab or other immunomodulatory or immunosuppressant therapies
             except the DMT's included in the inclusion criteria and methylprednisone for relapses
             within prior nine months.

          -  History of renal or liver disease.

          -  Consumption of green tea or supplements containing green tea or tea extract within 30
             days prior to enrollment.

          -  Participants may not participate in any other clinical trial involving investigational
             agents during the study, or within six months prior to enrolling in the study.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Polyphenon E, tea, or any of the inactive ingredients present in the
             active or placebo capsules, including gelatin.

          -  History of allergic reactions to gadolinium or any other condition contraindicated for
             MRI.

          -  Uncontrolled, clinically-relevant active illness (aside from MS) including, but not
             limited to, ongoing or active infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements.

          -  Any condition which would make the subject, in the opinion of the investigator,
             unsuitable for the study

          -  Inability to complete the baseline MRI scan

          -  Pregnant women

          -  Any underlying predisposition to gastrointestinal bleeding (peptic ulcer disease,
             gastritis, diverticulitis, colitis, hemorrhoids)
Clinical trial NCT02013375 (phase 2, status: terminated)
Conditions: sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: alemtuzumab, cyclophosphamide, sirolimus
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, CC(=O)CC(C1=CC=CC=C1)C1=C(O)C2=C(OC1=O)C=CC=C2
Eligibility criteria:

        Patient Eligibility:

          -  Patients with sickle cell disease are eligible if they have any of the following
             complications:

               -  Stroke or central nervous system event lasting longer than 24 hours

               -  Frequent vaso-occlusive pain episodes, defined as ≥ 3 per year requiring
                  emergency room, acute care center, or hospital admissions.

               -  Recurrent episodes of priapism, defined as ≥ 2 per year requiring emergency room
                  visits

               -  Acute chest syndrome with recurrent hospitalizations, defined as ≥ 2 lifetime
                  events

               -  Red-cell alloimmunization (≥ 2 antibodies) during long-term transfusion therapy

               -  Bilateral proliferative retinopathy with major visual impairment in at least one
                  eye

               -  Osteonecrosis of 2 or more joints

               -  Sickle cell nephropathy, defined by a GFR < 90mL/min/1.73m2 or the presence of
                  macroalbuminuria (urine albumin > 300 mg/g creatinine)

               -  Pulmonary hypertension, defined by a mean pulmonary artery pressure > 25mmHg

          -  Age 16-60 years

          -  Karnofsky performance status of 60 or higher

          -  Adequate cardiac function, defined as left ventricular ejection fraction ≥ 40%

          -  Adequate pulmonary function, defined as diffusion lung capacity of carbon monoxide ≥
             50% predicted (after adjustment for hemoglobin concentration)

          -  Estimated GFR ≥ 50mL/min as calculated by the modified MDRD equation

          -  ALT ≤ 3x upper limit of normal

          -  HIV-negative

          -  Patient is pregnant

          -  Patient is able and willing to sign informed consent

          -  Patient has an HLA-haploidentical relative
Clinical trial NCT02014376 (phase 2, status: completed)
Conditions: epidermolysis bullosa
ICD codes: Q81.0, Q81.1, Q81.2, Q81.8, Q81.9, L12.30, L12.35
Drugs: sd-101 dermal cream (3%), sd-101 dermal cream (6%), vehicle (sd-101 0%)
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Informed Consent form signed by the participant or the participant's legal
             representative; if the participant is under the age of majority but capable of
             providing assent, signed assent from the participant.

          -  Participant (or caretaker) was willing to comply with all protocol requirements.

          -  Diagnosis of Simplex, Recessive Dystrophic, or Junctional non-Herlitz EB.

          -  Participants 6 months of age and older.

          -  Participants had 1 target wound within a prespecified size range at study entry.

          -  Target wound was at least 21 days or older.

        Exclusion Criteria:

          -  Participants who did not meet all the entry criteria outlined in inclusion criteria.

          -  Selected target wound had clinical evidence of local infection.

          -  Use of any investigational drug within 30 days before enrollment.

          -  Use of immunotherapy or cytotoxic chemotherapy within 60 days before enrollment.

          -  Use of systemic or topical steroidal therapy within 30 days before enrollment (inhaled
             steroids and ophthalmic drops containing steroids were allowed).

          -  Use of systemic antibiotics within 7 days before enrollment.

          -  Current or former malignancy.

          -  Arterial or venous disorder resulting in ulcerated wounds.

          -  Diabetes mellitus.

          -  Pregnancy or breastfeeding during the study (a urine pregnancy test was performed at
             screening for female participants of childbearing potential).

          -  Females of childbearing potential who were not abstinent and not practicing a
             medically acceptable method of contraception.

          -  Known history of cardiac, hepatic, or renal disease.
Clinical trial NCT02016898 (phase 2, status: completed)
Conditions: primary open angle glaucoma
ICD codes: H40.1130, H40.1131, H40.1132, H40.1133, H40.1134, H40.1110, H40.1111
Drugs: mitomycin-c
SMILES: CO[C@]12[C@H]3N[C@H]3CN1C1=C([C@H]2COC(N)=O)C(=O)C(N)=C(C)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Men or women aged 18 years and older at screening.

          2. Diagnosis of chronic angle-closure glaucoma or open-angle glaucoma, phakic or
             pseudophakic, with visual field or optic disc changes characteristic of glaucoma.

          3. Suitable candidate for trabeculectomy with Ex-PRESS glaucoma filtration device with
             MMC in the superonasal quadrant in the study eye which the physician deems as
             medically necessary.

          4. Capable and willing to provide consent

        Exclusion Criteria:

          1. Unable or unwilling to provide consent

          2. Any previous ocular surgeries in the study eye preventing placement of the
             trabeculectomy with Ex-PRESS glaucoma filtration device with mitomycin-C in the
             superonasal quadrant

          3. Any previous glaucoma drainage devices in the study eye

          4. Any abnormality other than glaucoma in the study eye that could affect applanation
             tonometry.

          5. Presence or history of any abnormality or disorder that could interfere with the study
             procedure or prevent the successful completion of the study.

          6. Presence or history of uveitis within 10 years or any other ocular infection or
             inflammation within 14 days before day 1.

          7. Any significant unstable cardiovascular, hepatic, renal, respiratory,
             gastrointestinal, endocrine, immunologic, dermatologic, hematologic, neurologic, or
             psychiatric disease.

          8. Known Pregnancy or Breastfeeding

             Physical and Laboratory Findings

          9. Conjunctival scarring precluding a superonasal implantation location.

         10. Vitreous in the anterior chamber.

         11. Abnormality preventing reliable applanation tonometry in the study eye.
Clinical trial NCT02021292 (phase 2, status: completed)
Conditions: chronic thromboembolic pulmonary hypertension
ICD codes: I27.24
Drugs: macitentan, placebo
SMILES: CCCNS(=O)(=O)NC1=C(C(OCCOC2=NC=C(Br)C=N2)=NC=N1)C1=CC=C(Br)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Subject with CTEPH (WHO Group 4) judged as inoperable due to the localization of the
             obstruction being surgically inaccessible (i.e., distal disease).

          -  Female of childbearing potential must have a negative pre-treatment serum pregnancy
             test, be advised on appropriate methods of contraception, and agree to use 2 reliable
             methods of contraception.

        Exclusion Criteria:

          -  Previous pulmonary endarterectomy.

          -  Recurrent thromboembolism despite sufficient oral anticoagulants.

          -  Symptomatic acute pulmonary embolism in the 6-month period prior to randomization.

          -  Known moderate-to-severe restrictive lung disease (i.e., TLC < 60% of predicted value)
             or obstructive lung disease (i.e., FEV1 < 70% of predicted, with FEV1/FVC < 65%) or
             known significant chronic lung disease diagnosed by chest imaging (e.g., interstitial
             lung disease, emphysema).

          -  Acute or chronic conditions (other than dyspnea) that limit the ability to comply with
             study requirements in the 3-month period prior to Screening visit or during the
             Screening period.
Clinical trial NCT02021370 (phase 2, status: completed)
Conditions: anemia, renal insufficiency, chronic
ICD codes: D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9, N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: bay85-3934, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Women without childbearing potential

          -  Male or female subjects ≥ 18 years of age with anemia of chronic kidney disease (CKD)
             at screening

          -  Estimated glomerular filtration rate of < 60 mL/min/1.73 m2 (Modification of Diet in
             Renal Disease [MDRD] or the formula according to Matsuo, et al)

          -  Not on dialysis and not expected to begin dialysis during the treatment period of the
             study (at least 16 weeks from randomization)

          -  Not treated with any erythropoiesis-stimulating agent (ESA) within 8 weeks before
             randomization

          -  Mean screening Hb concentration </= 10.5 g/dL

          -  Body weight of 45 kg to 125 kg, inclusive, at screening

        Exclusion Criteria:

          -  Subjects with significant acute or chronic bleeding, such as overt gastrointestinal
             bleeding

          -  Chronic inflammatory disease that could impact erythropoiesis (e.g., systemic lupus
             erythematosis, rheumatoid arthritis, celiac disease) even if it is currently in
             remission

          -  Previous or concurrent cancer except cervical carcinoma in situ, treated basal cell
             carcinoma, superficial bladder tumors (Ta, Tis, and T1) or any cancer curatively
             treated > 3 years prior to randomization

          -  Subjects treated with any ESA within the 8 weeks before randomization

          -  Red blood cell (RBC) containing transfusion within the 8 weeks before randomization

          -  History of cardio- (cerebro-) vascular events (e.g., unstable angina, myocardial
             infarction, stroke, transient ischemic attack, deep vein thrombosis, pulmonary
             embolism) within the last 6 months from initial screening visit

          -  Severe rhythm or conduction disorders (e.g., HR < 50 or > 110 bpm, atrial flutter,
             prolonged QT > 500 msec, third degree atrioventricular [AV] block)

          -  New York Heart Association Class III or IV congestive heart failure

          -  Severe hepatic insufficiency (defined as alanine aminotransferase [ALT] or aspartate
             aminotransferase [AST] > 3 x the upper limit of normal [ULN], total bilirubin > 2
             mg/dL, or Child-Pugh B and C) or active hepatitis, in the investigator's opinion
Clinical trial NCT02021669 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: omega-3 supplement, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented coronary heart disease

          -  Diagnosis of major depression based on structured interview

        Exclusion Criteria:

          -  Moderate to severe cognitive impairment

          -  Meets DSM-5 criteria for depressive disorder due to a general medical condition or
             medication

          -  Major Axis I psychiatric disorder other than unipolar depression or an anxiety
             disorder, a high risk of suicide, or current substance abuse other than tobacco;

          -  Not expected to survive one year or physically unable to tolerate the study protocol

          -  Known sensitivity to sertraline or omega-3, or an allergy to fish oil or shellfish

          -  Taking an antidepressant or an omega-3 supplement at baseline

          -  Exempted by their cardiologist or primary care physician

          -  Refuses to provide informed consent

          -  Participating in a competing protocol or trial
Clinical trial NCT02023697 (phase 2, status: completed)
Conditions: prostatic neoplasms
ICD codes: B38.81, N42.31, Z87.430, N40.0, N40.1
Drugs: radium-223 dichloride (xofigo, bay88-8223)
SMILES: Cl[223Ra]Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the prostate

          -  Castration-resistant disease defined as:

               -  Serum testosterone level: ≤ 50 ng/dL (1.7 nmol/L)

               -  Bilateral orchiectomy or maintenance on androgen ablation therapy with
                  luteinizing-hormone-releasing hormone (LHRH) agonist or antagonist, or
                  polyestradiol phosphate

               -  Serum PSA (Prostate specific antigen) progression defined as 2 subsequent
                  increases in PSA over a previous reference value (a minimum of 2 ng/mL [μg/L]) OR

               -  Radiographic evidence of disease progression in bone (according to Prostate
                  Cancer Clinical Trials Working Group 2 [PCWG2] criteria) with or without PSA
                  progression

          -  Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 2. In case of
             ECOG PS 2, the PS has to be due to metastatic prostate cancer to the bone.

          -  Two or more skeletal metastases (≥ 2 hot spots) on bone scintigraphy within 8 weeks of
             randomization

        Exclusion Criteria:

          -  History of visceral metastasis, or visceral metastases

          -  Lymphadenopathy with lymph nodes exceeding 3 cm in short axis diameter

          -  Central nervous system (CNS) metastases

          -  Treatment with cytotoxic chemotherapy for prostate cancer within the previous 4 weeks
             prior to randomization, or planned treatment with cytotoxic chemotherapy agents for
             prostate cancer during the treatment period or follow-up

          -  Chronic conditions associated with non-malignant abnormal bone growth (e.g. confirmed
             Paget's disease of bone)

          -  Prior treatment with radium-223 dichloride

          -  Prior systemic radiotherapy and hemibody external radiotherapy
Clinical trial NCT02024932 (phase 2, status: completed)
Conditions: spinal and bulbar muscular atrophy
ICD codes: G71.00, G71.02, G71.11, G12.9, G71.09, N36.44, G12.1
Drugs: bvs857, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Genetic diagnosis of SBMA with symptomatic muscle weakness

          -  Able to complete 2 minute timed walk

          -  Serum IGF-1 level less than or equal to 170 ng/mL

        Key Exclusion Criteria:

          -  Medically treated diabetes mellitus or known history of hypoglycemia

          -  History of Bell's palsy

          -  Treatment with systemic steroids > 10 mg/day (or equivalent dose); androgens or
             androgen reducing agents; systemic beta agonists; or other muscle anabolic drugs
             within the previous 3 months

          -  History of cancer, other than non-melanomatous skin cancer

          -  Retinopathy

          -  Papilledema Other protocol defined inclusion/exclusion criteria may apply
Clinical trial NCT02030925 (phase 2, status: completed)
Conditions: gastroesophageal reflux
ICD codes: K21.9, K21.00, K21.01
Drugs: iw-3718, matching placebo
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Patient is between 18 and 65 years of age at the Screening Visit; females must not be
             pregnant or must not be breastfeeding;

          -  Patient has a confirmed diagnosis of gastroesophageal reflux disease, must be
             currently taking a proton pump inhibitor (PPI), and must be experiencing GERD symptoms
             as specified by the protocol.

        Exclusion Criteria:

          -  Patient may not meet any of the excluded conditions specified in the protocol;

          -  Patient is experiencing alarm symptoms such as GI bleeding, anemia, vomiting,
             dysphagia, or unexpected weight loss;

          -  Patient has a clinically significant hypersensitivity or allergies to any of the
             active ingredients or excipients in the study medication.